ISPOR 21ST ANNUAL INTERNATIONAL MEETING ISSUE PANEL CONSIDERS MCDA AS A POSSIBLE NEW PARADIGM IN HEALTH CARE DECISION MAKING

Published May 24, 2016
Washington, DC—May 24, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting Issue Panel 12—Multi-Criteria Decision Analysis: A New Paradigm in Health Care Decision Making? What Are the Current Status, Challenges, and Opportunities?—was held this afternoon in Washington, DC, USA. The Issue Panel moderator was James Dolan, MD, Professor, University of Rochester, Rochester, NY, USA. Panelists included:
  • Kevin Marsh, PhD, Executive Director, Evidera, London, UK
  • Mireille M. Goetghebeur, PhD, MEng, Global Scientist, LASER Analytica and School of Public Health, University of Montreal, Montreal, QC, Canada
  • Mabel Moreno Viscaya, PhD, Senior Economist, Instituto de Evaluación Tecnológica en Salud (IETS), Bogata, Colombia
Multiple criteria decision analysis (MCDA), an application of decision analytics that can help improve the quality of complicated decisions, is gaining significant interest in health care. MCDA application in health care decision making can also be subject to controversy. For example, while many MCDA methods are available, little guidance currently exists for how to choose the right technique for a particular problem. The ISPOR Multi-Criteria Decision Analysis in Health Care Decision Making Emerging Good Practices Task Force was established in 2014 to help fill this knowledge gap. The panel used content from a two-day workshop that convened MCDA experts from around the world to illustrate and spark discussion of the controversies and complexities of health care decisions. The panelists encouraged attendees to apply MCDA in health economics and outcomes research to provide a way to change the current paradigm in health care decision making. Additional information and resources on MCDA can be found on the ISPOR website, including: Presentations and slide decks from the ISPOR 21st Annual International meeting can be found here. Interested parties can follow news and developments from the meeting on social media using the hashtag #ISPORDC.

###

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×